How does 35H's PS Ratio compare to its peers?

35H is expensive based on its Price-To-Sales Ratio (46.6x) compared to the peer average (13.9x).

How does 35H's PS Ratio compare vs other companies in the DE Biotechs Industry?

35H is expensive based on its Price-To-Sales Ratio (46.6x) compared to the European Biotechs industry average (11.1x).

What is 35H's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 35H's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 35H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 35H's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Homology Medicines (DB:35H) - Stock Price, News & Analysis

35H Stock Overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. More details

35H fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 13.23% per year

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (€54M)

+ 1 more risk

Homology Medicines, Inc. Competitors

Medigene

XTRA:MDG1

€22.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Epigenomics

DB:ECX

€1.1m

Price History & Performance

Summary of all time highs, changes and price drops for Homology Medicines
Historical stock prices
Current Share Price	US$0.83
52 Week High	US$1.26
52 Week Low	US$0.31
Beta	-0.11
11 Month Change	5.06%
3 Month Change	73.64%
1 Year Change	4.98%
33 Year Change	-89.49%
5 Year Change	-96.65%
Change since IPO	-94.20%

Recent updates

Shareholder Returns

	35H	DE Biotechs	DE Market
7D	3.8%	-0.7%	0.2%
1Y	5.0%	-17.2%	8.5%

Return vs Industry: 35H underperformed the German Biotechs industry which returned 35.3% over the past year.

Return vs Market: 35H underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is 35H's price volatile compared to industry and market?
35H volatility
35H Average Weekly Movement	14.2%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: 35H's share price has been volatile over the past 3 months.

Volatility Over Time: 35H's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2015	7	n/a	www.homologymedicines.com

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.

Homology Medicines, Inc. Fundamentals Summary

How do Homology Medicines's earnings and revenue compare to its market cap?
35H fundamental statistics
Market cap	€49.80m
Earnings (TTM)	-€104.32m
Revenue (TTM)	€1.07m

46.6x

P/S Ratio

-0.5x

P/E Ratio

Is 35H overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
35H income statement (TTM)
Revenue	US$1.16m
Cost of Revenue	US$62.00m
Gross Profit	-US$60.85m
Other Expenses	US$52.12m
Earnings	-US$112.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.94
Gross Margin	-5,263.49%
Net Profit Margin	-9,771.71%
Debt/Equity Ratio	0%

How did 35H perform over the long term?

See historical performance and comparison

35H Stock Overview

Rewards

Risk Analysis

Homology Medicines, Inc. Competitors

XTRA:MDG1

€22.6m

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

DB:ECX

€1.1m

Price History & Performance

Recent News & Updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Share price stability

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

No longer forecast to breakeven

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

New 90-day high: €12.09

New 90-day high: €10.86

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

New 90-day low: €7.86

New 90-day low: €8.14

Third quarter 2020 earnings released: US$0.62 loss per share

Revenue beats expectations

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

New 90-day low - €8.36

New 90-day low - €8.97

First half earnings released

Shareholder Returns

Price Volatility

About the Company

Homology Medicines, Inc. Fundamentals Summary

46.6x

-0.5x

Earnings & Revenue